Movatterモバイル変換

Selatogrel

From Wikipedia, the free encyclopedia

P2Y12 inhibitor

Pharmaceutical compound

Selatogrel
Clinical data

Other names	ACT-246475
Legal status
Legal status	Investigational
Identifiers
IUPAC name [(2R)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid
CAS Number	1159500-34-1
PubChemCID	59534142
UNII	6DPK7O4PR7
ChEMBL	ChEMBL4297589
Chemical and physical data
Formula	C₂₈H₃₉N₆O₈P
Molar mass	618.628 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCCCOC(=O)N1CCN(CC1)C(=O)[C@H](CP(=O)(O)O)NC(=O)C2=CC(=NC(=N2)C3=CC=CC=C3)N4CC[C@@H](C4)OC
InChI InChI=1S/C28H39N6O8P/c1-3-4-16-42-28(37)33-14-12-32(13-15-33)27(36)23(19-43(38,39)40)30-26(35)22-17-24(34-11-10-21(18-34)41-2)31-25(29-22)20-8-6-5-7-9-20/h5-9,17,21,23H,3-4,10-16,18-19H2,1-2H3,(H,30,35)(H2,38,39,40)/t21-,23-/m0/s1 Key:FYXHWMQPCJOJCH-GMAHTHKFSA-N

Selatogrel is aP2Y₁₂ inhibitor^[1]^[2] that has been proposed as a treatment foracute myocardial infarction.^[3]

^Milluzzo RP, Franchina GA, Capodanno D, Angiolillo DJ (June 2020). "Selatogrel, a novel P2Y₁₂ inhibitor: a review of the pharmacology and clinical development".Expert Opinion on Investigational Drugs.29 (6):537–546.doi:10.1080/13543784.2020.1764533.PMID 32396484.
^Parker WA, Storey RF (March 2020). "Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y₁₂ receptor antagonist".Expert Opinion on Emerging Drugs.25 (1):1–6.doi:10.1080/14728214.2020.1729121.PMID 32064955.
^Gehin M, Storey RF, Bernaud C, Dingemanse J (2023)."Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction".Expert Opinion on Drug Metabolism & Toxicology.19 (10):697–708.doi:10.1080/17425255.2023.2266384.PMID 37795868.

Thispharmacology-related article is astub. You can help Wikipedia byexpanding it.

Hidden categories: